Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1210812
PUBLISHER: BCC Research | PRODUCT CODE: 1210812
Microbiome Therapeutics: Global Markets
PUBLISHED:
PAGES: 175 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Highlights:
The global market for microbiome therapeutics is estimated to increase from $164.8 million in 2022 to reach $1.5 billion by 2027, at a compound annual growth rate (CAGR) of 54.8% from 2022 through 2027.
Microbiome therapeutics market for GIT diseases is estimated to increase from $94.4 billion in 2022 to reach $262.3 billion by 2027, at a CAGR of 22.7% from 2022 through 2027.
Microbiome therapeutics market for infections is estimated to increase from $70.4 billion in 2022 to reach $224.2 billion by 2027, at a CAGR of 26.1% from 2022 through 2027.
Report Scope:
BCC Research's new report, Microbiome Therapeutics: Global Markets, provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2027. The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials). This study surveys the microbiome therapeutics market by application or disease segment: infectious diseases, metabolic diseases, cancer, gut-brain axis, and others. The market is assessed in the following geographic regions: North America, Europe, and emerging markets. Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada, and Latin America.
The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting growth of this market in the global context.
The new BCC report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and leading pipeline candidates. This chapter covers influential mergers and acquisitions and other collaborations or partnerships that happened during the evaluation period of this report.
Strengths, weaknesses, threats, and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.
The markets for prebiotics and probiotics labeled as nutritional or dietary supplements are excluded from this report. Prebiotics and probiotics are included when used in the context of microbiome therapy.
Report Includes:
- 32 data tables and 44 additional tables
- An up-to-date overview and analysis of the global and regional markets for microbiome therapeutics
- Analyses of the global market trends, with historic market revenue (sales data) for 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027
- Discussion of the industry growth driving factors and major technology challenges and issues affecting the market for microbiome therapeutics as a basis for projecting demand over the next few years (2022-2027)
- Estimation of the actual market size and revenue forecast for global microbiome therapeutics market in USD million terms, and corresponding market share analysis by technology type, application, and region
- Highlights of this innovation driven market covering current trends in genome sequencing industry, disease areas of application, clinical trials and their stages, and recent breakthrough innovations etc.
- Assessment of the recent industry structure for microbiome therapeutics, ongoing research (R&D) activities, analysis of competitive environment, and the COVID-19 impact on the marketplace
- Review of the patents and patent applications on microbiome therapeutics, and related scientific publications during the analysis period
- Competitive landscape of this market featuring leading biopharmaceutical companies, their product portfolios, financial updates, and market share analysis based on recent segmental revenues
- Profile description of the major market participants, including Assembly Biosciences, Finch Therapeutics, Second Genome, Evelo Biosciences, Ysopia Bioscience and Evelo Biosciences
Product Code: BIO205B
Table of Contents
Chapter 1 Introduction
- 1.1 Study Goals and Objectives
- 1.2 Reasons for Doing This Study
- 1.3 What's New in This Report?
- 1.4 Scope of Report
- 1.5 Information Sources
- 1.6 Methodology
- 1.7 Geographic Breakdown
- 1.8 Analyst's Credentials
- 1.9 BCC Custom Research
- 1.10 Related BCC Research Reports
Chapter 2 Summary and Highlights
- 2.1 Key Highlights
Chapter 3 Market and Technology Background
- 3.1 Benefits
- 3.2 The Human Microbiome
- 3.2.1 Different Microbiomes in Humans
- 3.2.2 Microbiome, Human Health and Disease
- 3.2.3 Technologies Aiding Microbiome Research
- 3.2.4 Microbiome Research Projects
- 3.3 Microbiome Therapeutics
- 3.3.1 Strategies for the Development of Microbiome Therapeutics
- 3.3.2 Microbiome Therapeutics Disease Areas
- 3.3.3 Regulatory Landscape for Microbiome Therapeutics
Chapter 4 Market Breakdown by Type of Therapeutic
- 4.1 Introduction
- 4.2 Market Overview
- 4.2.1 Market Revenue
- 4.2.2 Market Shares
- 4.3 Additive Microbiome Therapeutics
- 4.3.1 Fecal Microbiota Transplants (FMTs)
- 4.3.2 Live Biotherapeutic Products (LBPs)
- 4.3.3 Market Overview
- 4.3.4 Market Revenue
- 4.3.5 Market Shares
- 4.4 Modulatory Microbiome Therapeutics
- 4.4.1 Mechanism of Action
- 4.4.2 Current Status
- 4.4.3 Market Overview
- 4.4.4 Market Revenue
- 4.4.5 Market Shares
- 4.5 Subtractive Microbiome Therapeutics
- 4.5.1 Mechanism of Action
- 4.5.2 Current Status
- 4.5.3 Market Overview
- 4.5.4 Market Revenue
- 4.5.5 Market Shares
Chapter 5 Market Breakdown by Application
- 5.1 Introduction
- 5.1.1 Market Revenue
- 5.1.2 Market Shares
- 5.2 Infections
- 5.2.1 Clostridium Difficile Infection (CDI)
- 5.2.2 Urinary Tract Infection (UTI)
- 5.2.3 COVID-19
- 5.2.4 Market Overview
- 5.2.5 Market Revenue
- 5.3 Gastrointestinal (GIT) Diseases
- 5.3.1 Market Overview
- 5.3.2 Market Revenue
- 5.4 Metabolic Diseases
- 5.4.1 Market Overview
- 5.4.2 Market Revenue
- 5.5 Cancer
- 5.5.1 Market Overview
- 5.5.2 Market Revenue
- 5.6 Gut-Brain Axis Diseases
- 5.6.1 Market Overview
- 5.6.2 Market Revenue
- 5.7 Other Diseases
- 5.7.1 Market Overview
- 5.7.2 Market Revenue
- 5.8 Regional Markets Globally
- 5.8.1 Market Shares
Chapter 6 Industry Structure
- 6.1 Investment in Microbiome Therapeutics
- 6.1.1 Public Funding Initiatives
- 6.1.2 Private Funding Initiatives
- 6.2 Collaborations and Partnerships
- 6.3 Licensing and Manufacturing Agreements
- 6.4 Mergers and Acquisitions
- 6.5 Leading Market Players in the Market for Microbiome Therapeutics
- 6.5.1 Leading Market Players in Market for Additive Microbiome Therapeutics
- 6.5.2 Leading Market Players in the Market for Modulatory Microbiome Therapeutics
- 6.5.3 Leading Market Players in the Market for Subtractive Microbiome Therapeutics
- 6.6 BCC Research Select Insights from Industry Leaders
Chapter 7 Patent Analysis
- 7.1 Patent Analysis
- 7.1.1 Patents by Year
- 7.1.2 Patents by Type
- 7.1.3 Patents by Type of Disease
- 7.1.4 Patents by Company
- 7.1.5 Patents by Country
- 7.1.6 Patents by Assignee
Chapter 8 Clinical Trials
- 8.1 Clinical Trials by Disease Category
- 8.1.1 Distribution Shares of Clinical Trials
- 8.2 Clinical Trials by Type of Therapeutic
- 8.2.1 Distribution Shares of Clinical Trials by Type of Therapeutic
- 8.3 Clinical Trials by Company
- 8.3.1 Distribution Shares of Clinical Trials by Company
- 8.3.2 Microbiome Therapeutics in Discovery and Preclinical Development
- 8.3.3 Microbiome Therapeutics in Phase 3 Clinical Trials
Chapter 9 Analysis of Market Opportunities
- 9.1 SWOT Analysis
- 9.1.1 Strengths of Market for Microbiome Therapeutics
- 9.1.2 Challenges in the Market for Microbiome Therapeutics
- 9.1.3 Opportunities in the Market for Microbiome Therapeutics
- 9.1.4 Threats to the Market for Microbiome Therapeutics
Chapter 10 Company Profiles
- 4D PHARMA
- AO BIOME LLC
- ASSEMBLY BIOSCIENCES INC.
- ARMATA PHARMACEUTICALS
- AZITRA INC.
- BIOMICA
- BIOMX
- CHAIN BIOTECHNOLOGY LTD.
- ELIGO BIOSCIENCE SAS
- ENTEROME SA
- EVELO BIOSCIENCES
- FINCH THERAPEUTICS GROUP INC.
- INTRALYTIX INC.
- MAAT PHARMA
- OSEL INC.
- PYLUM BIOSCIENCES INC.
- QUORUM INNOVATIONS LLC
- REBIOTIX INC. (A FERRING COMPANY)
- SECOND GENOME
- SENDA BIOSCIENCES INC.
- SERES THERAPEUTICS INC.
- SFA THERAPEUTICS INC.
- SYNLOGIC
- THERIVA BIOLOGICS INC.
- VEDANTA BIOSCIENCES INC.
- YSOPIA BIOSCIENCE INC.
Chapter 11 Appendix: Acronyms
Product Code: BIO205B
List of Tables
- Summary Table : Global Market for Microbiome Therapeutics, by Type of Disease, Through 2027
- Table 1 : Technology for Microbiome Research
- Table 2 : Dysbiosis in Microbiome
- Table 3 : Leading Pharmaceutical/Microbiome Therapeutics Partnerships
- Table 4 : Global Market for Microbiome Therapeutics, by Type, Through 2027
- Table 5 : Global Market Shares of Microbiome Therapeutics, by Type, 2027
- Table 6 : LBPs in Microbiome Therapeutics
- Table 7 : Global Market for Additive Microbiome Therapeutics, by Type, Through 2027
- Table 8 : Global Market Shares of Additive Microbiome Therapeutics, by Type, 2027
- Table 9 : Modulatory Microbiome Therapeutics
- Table 10 : Global Market for Modulatory Microbiome Therapeutics, by Type, Through 2027
- Table 11 : Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2027
- Table 12 : Global Market for Subtractive Microbiome Therapeutics, by Type, Through 2027
- Table 13 : Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2027
- Table 14 : R&D Expenditures in Microbiome Therapeutics, by Company, 2017-2019
- Table 15 : Global Market for Microbiome Therapeutics, by Type of Disease, Through 2027
- Table 16 : Global Market Shares of Microbiome Therapeutics, by Type of Disease, 2027
- Table 17 : Microbiome Therapeutics for Infections
- Table 18 : Global Market for Microbiome Therapeutics for Infections, by Region, Through 2027
- Table 19 : Microbiome Therapeutics for GIT Diseases
- Table 20 : Global Market for Microbiome Therapeutics for GIT Diseases, by Region, Through 2027
- Table 21 : Microbiome Therapeutics for Metabolic Diseases
- Table 22 : Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, Through 2027
- Table 23 : Microbiome Therapeutics for Cancer
- Table 24 : Global Market for Microbiome Therapeutics for Cancer, by Region, Through 2027
- Table 25 : Microbiome Therapeutics for Gut-Brain Axis Diseases
- Table 26 : Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, Through 2027
- Table 27 : Microbiome Therapeutics for Other Diseases
- Table 28 : Global Market for Microbiome Therapeutics for Other Diseases, by Region, Through 2027
- Table 29 : Global Market for Microbiome Therapeutics, by Region, Through 2027
- Table 30 : Global Market Shares of Microbiome Therapeutics, by Region, 2027
- Table 31 : Historical Funding Activity, Microbiome Therapeutics, 2015 and 2016
- Table 32 : Public Funding, Microbiome Therapeutics, 2018-2022
- Table 33 : Venture Funding, Microbiome Therapeutics, 2017-Aug. 2020
- Table 34 : Collaborations and Partnerships in the Market for Microbiome Therapeutics, 2017-2022
- Table 35 : Licensing and Manufacturing Agreements in the Market for Microbiome Therapeutics, 2017-Aug. 2020
- Table 36 : Leading Developers of Additive Microbiome Therapeutics, 2022
- Table 37 : Leading Developers of Modulatory Microbiome Therapeutics, 2022
- Table 38 : Leading Developers of Subtractive Microbiome Therapeutics, 2022
- Table 39 : Patents Issued on Microbiome Therapeutics, by Year, 2017-2022
- Table 40 : Patents Issued on Microbiome Therapeutics, by Type, 2017-2022
- Table 41 : Patents Issued on Microbiome Therapeutics, by Type of Disease, 2017-2022
- Table 42 : Patents Issued on Microbiome Therapeutics, by Company, 2017-2022
- Table 43 : Patents Issued on Microbiome Therapeutics, by Country, 2017-2022
- Table 44 : Patents Issued on Microbiome Therapeutics, by Assignee, 2017-Aug. 2020
- Table 45 : Distribution of Clinical Trials on Microbiome Therapeutics, by Type of Disease, 2022
- Table 46 : Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Disease, 2022
- Table 47 : Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Therapeutic
- Table 48 : Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Therapeutic
- Table 49 : Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Company
- Table 50 : Distribution Shares of Clinical Trials on Microbiome Therapeutics for the Top 10 Companies
- Table 51 : Microbiome Therapeutics, Discovery and Preclinical Development
- Table 52 : Microbiome Therapeutics in Phase 3 Clinical Trials
- Table 53 : 4D Pharma: Pipeline
- Table 54 : AO Biome: Pipeline
- Table 55 : Assembly Biosciences: Pipeline
- Table 56 : Armata Pharmaceuticals: Pipeline
- Table 57 : Azitra: Pipeline
- Table 58 : Biomica: Pipeline
- Table 59 : BiomX: Pipeline
- Table 60 : Enterome: Pipeline
- Table 61 : Evelo Biosciences: Pipeline
- Table 62 : Finch Therapeutics: Pipeline
- Table 63 : Intralytix: Pipeline
- Table 64 : MaaT Pharma: Pipeline
- Table 65 : Osel: Pipeline
- Table 66 : Quorum Innovations: Pipeline
- Table 67 : Rebiotix: Pipeline
- Table 68 : Second Genome: Pipeline
- Table 69 : Seres Therapeutics: Pipeline
- Table 70 : SFA Therapeutics: Pipeline
- Table 71 : Synlogic: Pipeline
- Table 72 : Theriva Biologics: Pipeline
- Table 73 : Vedanta Biosciences: Pipeline
- Table 74 : Ysopia Bioscience: Pipeline
- Table 75 : Acronyms Used in This Report
List of Figures
- Summary Figure : Global Market for Microbiome Therapeutics, by Type of Disease, 2021-2027
- Figure 1 : Differences between the Human Genome and the Microbiome
- Figure 2 : Bacterial Distribution, by Body Site
- Figure 3 : Essential Functions, Human Microbiome
- Figure 4 : Dysbiosis and Human Health
- Figure 5 : Summary of NIH Funding for Microbiome Research, 2012-2016
- Figure 6 : Global Market for Microbiome Therapeutics, by Type, 2021-2027
- Figure 7 : Global Market Shares of Microbiome Therapeutics, by Type, 2027
- Figure 8 : Global Market for Additive Microbiome Therapeutics, by Type, 2021-2027
- Figure 9 : Global Market Shares of Additive Microbiome Therapeutics, by Type, 2027
- Figure 10 : Global Market for Modulatory Microbiome Therapeutics, by Type, 2021-2027
- Figure 11 : Global Market Shares of Modulatory Microbiome Therapeutics, by Type, 2027
- Figure 12 : Global Market for Subtractive Microbiome Therapeutics, by Type, 2021-2027
- Figure 13 : Global Market Shares of Subtractive Microbiome Therapeutics, by Type, 2027
- Figure 14 : Global Market for Microbiome Therapeutics, by Type of Disease, 2021-2027
- Figure 15 : Global Market Shares of Microbiome Therapeutics, by Type of Disease, 2027
- Figure 16 : Global Market for Microbiome Therapeutics for Infections, by Region, 2021-2027
- Figure 17 : Global Market for Microbiome Therapeutics for GIT Diseases, by Region, 2021-2027
- Figure 18 : Global Market for Microbiome Therapeutics for Metabolic Diseases, by Region, 2021-2027
- Figure 19 : Global Market for Microbiome Therapeutics for Cancer, by Region, 2021-2027
- Figure 20 : Global Market for Microbiome Therapeutics for Gut-Brain Axis Diseases, by Region, 2021-2027
- Figure 21 : Global Market for Microbiome Therapeutics for Other Diseases, by Region, 2021-2027
- Figure 22 : Global Market for Microbiome Therapeutics, by Region, 2021-2027
- Figure 23 : Global Market Shares of Microbiome Therapeutics, by Region, 2027
- Figure 24 : Patents Issued on Microbiome Therapeutics, by Year, 2017-2022
- Figure 25 : Patents Issued on Microbiome Therapeutics, by Type, 2017-2022
- Figure 26 : Patents Issued on Microbiome Therapeutics, by Type of Disease, 2017-2022
- Figure 27 : Patents Issued on Microbiome Therapeutics, by Company, 2017-2022
- Figure 28 : Patents Issued on Microbiome Therapeutics, by Country, 2017-2022
- Figure 29 : Patents Issued on Microbiome Therapeutics, by Assignee, 2017-Aug. 2020
- Figure 30 : Distribution Shares of Clinical Trials on Microbiome Therapeutics, by Type of Disease, 2022
- Figure 31 : Distribution Shares of Clinical Trials on Microbiome Therapeutics by Type of Therapeutic
- Figure 32 : Distribution Shares of Clinical Trials on Microbiome Therapeutics for the Top 10 Companies
- Figure 33 : SWOT Analysis of the Market for Microbiome Therapeutics
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.